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Background:  The  clinical  use  of  Chinese  herbal  medicine  granules  is  gradually  increasing.  However,  there
is still  no  systematic  review  comparing  the effectiveness  and  safety  of  granules  with  the  more  traditional
method  of herbal  decoctions.
Method:  A  literature  search  was  conducted  using  China  National  Knowledge  Infrastructure  Databases
(CNKI),  Chinese  Science  and  Technology  Periodical  Database  (VIP),  China  Biomedical  Database  web (CBM),
Wanfang  Database,  PubMed,  and  the  Cochrane  Library  until  March  10,  2011.  Clinical  controlled  trials
(CCTs)  including  randomized  trials  (RCTs)  comparing  the  effectiveness  and  safety  between  Chinese  herbal
medicine  granules  and  decoction  were  included.  Two authors  conducted  the  literature  searches,  and
extracted  data  independently.  The  assessment  of  methodological  quality  of  RCTs  was  based  on the risk  of
bias  from  the  Cochrane  Handbook,  and  the  main  outcome  data  of  trials  were  analyzed  by  using  RevMan
5.0  software.  Risk  ratio  (RR)  or mean  difference  (MD)  with  a 95% conﬁdence  interval  (CI)  were used  as
effect measure.
Results:  56  clinical  trials  (n = 9748)  including  42  RCTs  and  14 CCTs  were  included,  and  all  trials  were
conducted  in  China  and  published  in  Chinese  literature.  40 types  of  diseases  and  15  syndromes  of tra-
ditional  Chinese  medicine  (TCM)  were  reported.  Granules  were  provided  by pharmaceutical  companies
in 13 trials.  The  included  RCTs  were  of  generally  low  methodological  quality:  7 trials  reported  adequate
randomization  methods,  and  2  of these  reported  allocation  concealment.  10 trials  used blinding,  of  which
5  trials used  placebo  which  were  delivered  double  blind  (blinded  participants  and  practitioners).  98.2%
(55/56)  of  studies  showed  that  there  was  no  signiﬁcant  statistical  difference  between  granules  and  decoc-
tions of  Chinese  herbal  medicine  for their  effectiveness.  No severe  adverse  effects  in either  group  were
reported.
Conclusions:  Due  to  the  poor  methodological  quality  of  most  of  the included  trials,  it is not  possible  to
reach  a deﬁnitive  conclusion  whether  both  Chinese  herbal  medicine  granules  and  decoctions  have  the
same  degree  of effectiveness  and  safety  in  clinical  practice,  but  this  preliminary  evidence  supports  the
continued  use  of granules  in  clinical  practice  and  research.  Standardization  of  granules  and  further  more
rigorous  pharmacological,  toxicological  and  clinical  studies  are  needed  to  demonstrate  the equivalence
with  decoctions.∗ Corresponding author at: Center for Evidence-Based Chinese Medicine, Beijing
niversity of Chinese Medicine, 11 Bei San Huan Dong Lu, Chaoyang District, Beijing,
hina, 100029. Tel.: +86 10 64286757; fax: +86 10 64286760.
∗∗ Corresponding author at: Complementary Medicine Research Unit, Dept
rimary Medical Care, University of Southampton, Aldermoor Health Centre, Alder-
oor Close, Southampton SO16 5ST, United Kingdom.
E-mail addresses: ﬂower.power@which.net (A. Flower), jianping l@hotmail.com
J.  Liu).
378-8741     ©   2012 Elsevier Ireland Ltd. 
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1. Background
Prolonged boiling or ‘decocting’ is the earliest and most pop-
ular method of preparing herbal medicines in the practice of
traditional Chinese medicine (TCM). The composition of herbs
within a decoction is ﬂexible and can be revised according to
the condition of a patient, deﬁned according to TCM syndrome
differentiation and treatment principles. However, decoctions
Open access under CC BY-NC-ND license.have some disadvantages, such as the difﬁculties in ensuring
quality control of the herbal ingredients, the time and inconve-
nience they required to prepare, the practical problems relating
to their transportation and storage, the difﬁculty in ensuring
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dequate quality control of the herbal ingredients, and the
equirement to consume a large volume of unpleasant tast-
ng medicine. These obstacles can reduce compliance and may
nterfere with Chinese herbal medicine (CHM) treatment. His-
orically different kinds of formulation have been developed in
esponse to these shortcomings. These include traditional prepa-
ations of wan (pills), san (powder), gao (ointment), dan (another
ype of pill used in TCM) and the modern formulations of
ranules (ke li ji), oral liquids, capsules, tablets, and even injec-
ions.
Since granules may  retain the advantages of decoctions and
lso address the problems of quality control, preparation, and
dministration that occur with decoctions, their use has increased
ramatically both within China and other Asian countries and
egions. In Taiwan, Japan and South Korea research into granules
egan in the 1970s, and has led to rapid growth in this sector of
he herbal market. In Japan, more than 400 kinds of granules have
een developed, 148 Kampo granule herbal drugs were covered
y National Health Insurance Fund, and 86% of Japanese medical
octors use granules in their clinical practice (Edwin Lowell and
obuo, 2004). In South Korean, more than 300 kinds of concen-
rated granules have been developed and are now covered by health
nsurance (Zhang et al., 2000). Compared with Taiwan, Japan and
outh Korean, the mainland of China’s research and development
n this ﬁeld has been relatively slower. Although Chinese herbal
edicine granules were ﬁrst included in the 1977 edition of Chinese
harmacopoeia (zhong guo yao dian) (Yuan, 1999), these ‘granules’
ere developed from patent medicine formulations and did not
nclude single herbal granules that could be used for individualized
rescriptions. Until 1987, the Chinese Ministry of Health required
he reform of TCM formulations in order to improve their effective-
ess and to ensure adequate protection for endangered Chinese
edicinal plants. Therefore, after their initial production and a
eriod of evaluation about 4 years, Chinese manufactured gran-
les for individualized prescriptions were ﬁrst produced in 1992,
nd the ﬁrst group of herbal pharmaceutical companies producing
ranules were ofﬁcially approved by the Chinese State Administra-
ion of TCM in 1993. Currently, Chinese pharmaceutical companies
ave developed more than 600 kinds of individual herb gran-
les and 200 kinds of herbal formulae, which have been widely
sed in clinical practice (Jia and Zhang, 2005; Li, 2006; Ltd, 2011).
ranules were covered by basic medical insurance in Beijing in
pril 2009.
With the development and wide use of granules, their effec-
iveness and safety have become an increasing focus for research.
ow do the effectiveness and safety of granules’ compare with
ecoctions? Can granules be used as a substitute to traditional
ecoctions? There is considerable confusion and uncertainty in
oth herbal medicine producers and consumers in regard to these
ssues (Zhao, 1996; Yuan, 1999; Cheng, 2000; Xia, 2000; Li and
hen, 2010). Within a complex Chinese herbal formula, a variety
f chemical reactions may  occur during preparation. Differences
n the detail of manufacture (boiling, desiccation and granulation)
ay  affect dissolution rates and change the proportion of avail-
ble compounds within a formula (Yuan, 1999; Zhang and Jiang,
005; Yu et al., 2010). There is some chromatographic evidence
hat contents of constituents and active components in a herbal
ecoction may  exhibit a different high-performance liquid chro-
atography (HPLC) ﬁngerprint chromatogram to those found in
n identical mixture of granules dissolved in boiling water (Chen
t al., 2006; Ma  et al., 2006). In addition, in China the price of gran-
les is higher than dried Chinese herbs used in decoctions and
his has limited the use of granules (Zhang and Jiang, 2005; Li,
006; Liu, 2008; Li and Chen, 2010). In the West the converse is
rue and powders are considerably cheaper to use than decocted
erbs.acology 140 (2012) 555– 567
In response to this confusion clinical studies comparing the
effectiveness and safety of decoctions and granules have been
published over the previous 3 decades, but no systematic review
of these studies has been published. The aim of this current review
is to examine these data to evaluate the effectiveness and safety
of granules in comparison with decoctions, in order to address this
confusion.
2. Materials and methods
2.1. Search strategy
A search strategy was  designed to search all the available
literature. We  searched the Chinese National Knowledge Infras-
tructure Databases (CNKI) (1979–2011), the Chinese Science
and Technology Periodical Database (VIP) (1989–2011), the Chi-
nese Biomedical Database web  (CBM) (1978–2011), the Wanfang
Database (1985–2011), PubMed (1966–2011), and the Cochrane
Library (Issue 3, 2011). All the searches ended at 10th March 2011.
There was no limitation on language or publication type. The search
terms included “decoction” and “granules”. Two authors (Luo and
Li) conducted the literature search independently. Articles were
screened according to the title and then selected after abstracts
were read. The full text was  downloaded if the study met  the inclu-
sion criteria.
2.2. Inclusion criteria
Studies meeting the following three criteria were included
in this review: (1) Type of studies: randomized controlled trials
(RCTs), clinical controlled trials (CCTs). (2) Type of interventions:
the study was  designed to compare the effectiveness and safety of
granules and decoctions, or if the clinical trial included more than
two kinds of interventions, at least of which one was a decoction
group and the other one was granule group. (3) The proportions of
herbal medicine composition in the decoction and granules were
the same.
2.3. Exclusion criteria
The following kinds of studies were excluded: (1) Multiple pub-
lications reporting the same data of patients. (2) Lack of basic
information on participants or interventions. (3) Inconsistency in
intervention between treatment and control group. (4) Interven-
tions for external use.
2.4. Assessment methods
2.4.1. Searching for studies
Searching for studies was carried out by using criteria from the
Cochrane Reviewers’ Handbook 5.0.2 (Higgins and Green, 2009):
(1) Search results from different databases were imported into the
document management software Note Express 2.0; (2) Repeated
and non-relevant studies were rejected by screening the title and
abstract; (3) The full text of studies of potential relevance to the
review were downloaded. (4) Repeated studies and publications
were removed. (5) In instances of missing information the main
researcher of the study was  contacted for clariﬁcation. (6) Studies
for inclusion were identiﬁed according to the inclusion criteria. (7)
Finally a decision was made whether or not to include the study.
Steps 1–5 were carried on by Luo, 6–7 steps were carried on by Luo
and Li independently. They also cross checked the results with each
other. Disagreements were resolved by discussion or submitting to
the third researcher (Liu).
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.4.2. Methodological quality assessment
Evidence from an RCT is considered as the gold standard for ther-
peutic evaluation, so we speciﬁcally evaluated the methodological
uality of RCTs in this review. Two authors (Luo and Li) evaluated
he quality of included RCTs. Assessment of the methodological
uality of RCTs was conducted in accordance with criteria from the
ochrane Reviewers’ Handbook 5.0.2 (Higgins and Green, 2009).
e assessed studies according to the risk of bias for each impor-
ant outcome within the included trials, taking into account the
dequacy of the generation of the allocation sequence, allocation
oncealment, blinding and outcome reporting. The quality of all
he included trials was categorized as low/unclear/high risk of
ias. Trials that met  all the criteria were categorized as low risk
f bias, those that met  none of the criteria were categorized as
igh risk of bias, and the others were categorized as unclear risk of
ias if insufﬁcient information was available to make a judgment.
isagreements were submitted to JP Liu to resolve.
.4.3. Data extraction and analysis
A data extraction form was designed by all the authors. Two
uthors (Luo and Li) extracted the data independently. Data was
nputted into Microsoft Excel. Items in the form included (1) cita-
ions (author, title, journal, year, issue, volume, and page); (2)
ethodological character of trials; (3) participants (sample size,
isease); (4) the nature of the interventions; (5) outcome mea-
ures; (6) a summary of results; (7) adverse effects; and (8) health
conomic outcomes.
The main outcomes data of the trials were analyzed by using
evMan 5.0 software. The efﬁcacy measure was  risk ratio (RR)
ith a 95% conﬁdence interval (CI) for dichotomous data or
ean difference (MD) with a 95% CI for continuous data. Meta-
nalysis was to be used if the trials had a good homogeneity
f study design, participants, interventions, control, and outcome
easures.
. Results
.1. Basic information of studies
After a primary search of 6 electronic databases, 700 citations
ere identiﬁed, 28 of which were identiﬁed from PubMed and
ochrane Library. However the majority of these were excluded due
o their obvious ineligibility after reading the title/abstract or their
epeated mention in different databases. 87 studies were included
n the initial analysis. After reading the full text of each article,
6 trials met  the inclusion criteria and were included in the ﬁnal
eview, including 42 RCTs, 14 CCTs (Fig. 1). All the included stud-
es were published in Chinese. A study identiﬁed in the Cochrane
ibrary met  the inclusion criteria but the full text was  not available,
herefore, the full article was downloaded from a Chinese Journal
atabase according to its’ citation (Liang and Li, 1995).
9748 patients were involved in the included 56 trials. The mean
ample size of trials was 174, the minimum was  30 and maxi-
um  was 1982. All the trials were carried out in China. There
as a diverse distribution of diseases or TCM syndromes, with
0 diseases diagnosed according to modern medicine and 15 syn-
romes diagnosed according to TCM. Participants in some trials
ere diagnosed by a combination of modern medicine and TCM.
he majority of interventions (52/56) were oral use; interventions
n 4 trials used enemas (Pan et al., 2005; Lv et al., 2007; Zhou et al.,
009; Xie and Li, 2010). More details of the trials are presented in
able 1.
According to our pre-deﬁned methodological quality criteria, no
rial could be considered as having a low risk of bias, and the major-
ty (76.2%, 32/42) of the included RCTs were evaluated as having aacology 140 (2012) 555– 567 557
high risk of bias. None of the trials reported sample size calcula-
tion; 7 trials (Liang and Li, 1995; Lv et al., 2003; Liu et al., 2005;
Kuang et al., 2008; Lu et al., 2008; Wei  et al., 2009a,b) described
adequate randomization procedures (such as use of a random num-
ber table or computer generated random numbers), 2 of these
(Lu et al., 2008; Wei  et al., 2009b)  reported allocation conceal-
ment; 10 trials (Xu et al., 1998; Liu et al., 2005; Lv et al., 2007;
Lu et al., 2008; Kuang et al., 2008; Huang and Zhu, 2009; Liao et al.,
2009; Wang et al., 2009; Wei  et al., 2009b; Xie and Li, 2010) men-
tioned blinding, of which 5 (Liu et al., 2005; Lu et al., 2008; Wang
et al., 2009; Wei  et al., 2009a; Huang and Zhu, 2009) reported that
they used a placebo control. Other than for Liu’s trial, placebos
made from granules and decoctions were provided by pharmaceu-
tical companies in the other 5 trials. In Huang, Liu, Lu and Wei’s
trials, matched placebos were used to blind participants and prac-
titioners; that is, in intervention group, patients received both real
granules and placebo decoctions, while patients in control group
received both real decoctions and placebo granules, which made
the blind feasible. Moreover, both placebo decoction and gran-
ules were indistinguishable from the real treatment with respect
to color, smell and packaging. In Lv’s trial (Lv et al., 2007), gran-
ules and decoction were prepared using the same packaging in the
form of dark liquid, for which the color and smell were the same.
All the packaging work was  prepared in the hospital pharmacy.
When these packages arrived at participants and practitioners loca-
tion, they were blind to the intervention. So there was  no need to
use a placebo in this study. The other 4 trials did not report any
details on how blinding was  achieved. None of trials included a
blinded assessor. Five trials (Liu et al., 2005; Lv et al., 2007; Lu et al.,
2008; Zhou et al., 2008; Wei  et al., 2009b)  reported the number
of dropouts, but none of them used an intention-to-treat analy-
sis.
Only 3 trials (Huang and Zhu, 2009; Wang et al., 2009; Wei  et al.,
2009b)  mentioned that their research used a non-inferiority study
design to compare the effectiveness of decoction and granules.
3.2. Effectiveness and safety evaluation
3.2.1. Selection of outcome measure
Due to the diversity of diseases in the included trials, the out-
comes measures were similarly diverse. The majority of trials
used complex outcomes measures containing symptoms, signs,
and laboratory indexes, to evaluate the effectiveness of interven-
tions. However the outcomes were also frequently aggregated and
divided into four basic categories of therapeutic response: clinical
remission (or clinical completely remission), marked effect, effec-
tive, and ineffective. The deﬁnitions of these were similar in all the
trials. For example, ineffective was deﬁned as “there is no signiﬁ-
cant difference or deterioration in symptoms, signs, or laboratory
indices before and after treatment”; the effective was  deﬁned as
“there is an improvement in symptoms, signs, or laboratory indices
after treatment”. Marked effective was deﬁned as “there is a signif-
icant improvement in symptoms, signs, or laboratory indices after
treatment”; and the clinical remission was  deﬁned as “the clinical
symptoms and signs disappeared, and laboratory indices return to
normal after treatment” (Liu et al., 2005; Lv et al., 2007; Lu et al.,
2008; Zhou et al., 2008; Wei  et al., 2009b).  In addition, some tri-
als reported disease speciﬁc outcomes. For example, an RCT on
uterine ﬁbroids (Yang et al., 2008) reported the change of uterine
volume.
3.2.2. Estimate effect of decoction and granules
45 trials reported outcomes as dichotomous data, so RR was
used in their evaluation. 11 trials reported laboratory outcomes
or outcomes providing continuous data, so MD  with a 95% CI
was used. The results showed that, with the exception of 1 RCT
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Table 1
Characteristics of studies.
Study Design Fund Sample size Granule
source
Disease and TCM
diagnosis
Groups Formula and its
component
Medicine
dosage (G
vs D)
Decoction
prepara-
tion
Outcome measure
Tan and
Tan
(2010)
CCT N 150 PC (U) Cervical spondylosis 3 Self-made
formula (S)
U U ER, cost-effect analysis
Yang  et al.
(2010)
RCT Y 58 U Chronic atrophic
gastritis (deﬁciency
of stomach yin)
3  Self-made
formula (S) =
U ER, improvement from
gastroscopy and
pathology
Qin  (2010) RCT N 63 PC (U) Essential
hypertension
3 tianma gouteng
yin (C)
U U blood pressure,
symptoms of RCM,
blood biochemistry
Xie  and Li
(2010)
RCT N 101 PC (U) Ulcerative colitis
(yang deﬁciency of
spleen and kidney)
2 sishen wan  (S)
=
R ER, TCM syndrome
scores, Sutherland
index
Liao  et al.
(2009)
RCT Y 60 PC (F) Stroke recovery (qi
deﬁciency and
blood stasis)
2 buyang huanwu
tang (C)
1/3 R ER, TCM syndrome
scores
Wei  et al.
(2009b)
RCT Y 153 PC (F) Chronic gastritis,
functional
dyspepsia (stomach
deﬁciency)
3 liangfu wan (S) U R ER
Huang and
Zhu
(2009)
RCT Y 116 PC (F) Acute and chronic
bronchitis (phlegm
and heat)
2 Self-made
formula (C)
U R ER
Zhou  et al.
(2009)
RCT N 40 U Chronic pelvic
inﬂammation
2 Self-made
formula (C)
= R ER
Chen  et al.
(2009)
RCT N 105 PC (F) Chronic gastritis 2 Self-made
formula (S)
= R ER, symptoms score
Wei  et al.
(2009a)
RCT N 130 PC (F) Chronic kidney
disease stage of 4 or
5  (deﬁciency of qi
and blood, wetness
internal)
3 Self-made
formula (S)
< R scores of symptoms
and SGA, function
indexes of nutritional,
renal and
hematopoietic
Zhao  et al.
(2009)
RCT N 100 PC (U) Acute bronchitis
children (wind-heat
invading lung)
2 Self-made
formula (S)
= U ER, TCM syndrome
Xiang  et al.
(2009)
CCT Y 335 PD Chronic hepatitis B 2 Self-made
formula (S)
= R liver function, ER
Zhang  and
Cai
(2009)
RCT N 65 PC (F) Acute sinusitis
(gallbladder heat
stagnation)
2 Self-made
formula (S)
U U ER
Wang et al.
(2009)
RCT Y 88 PC (U) Papular urticaria
(wind-heat)
3 Self-made
formula (S)
U R ER
Zhou  et al.
(2008)
RCT N 80 PC (F) Insomnia 2 Self-made
formula (S)
= R ER, Pittsburgh Sleep
Quality Index (PSQI),
TCM syndrome scores
Lu  et al.
(2008)
RCT Y 150 PC (U) Diarrhea (cold
wetness)
3 huoxiang
zhengqi san (S)
= R ER, improvement of
TCM symptoms
Yang  et al.
(2008)
RCT N 180 PC (U) Hysteromyoma
/ﬁbroids
3 Self-made
formula (S)
U U volume of uterine
ﬁbroids, ER
Li  et al.
(2008)
RCT N 50 PC (U) Infantile anorexia
(spleen-stomach
disharmony)
2 Unclear (S) = U ER, symptoms score,
weight, intake per date,
urinary excretion rate
of  xylose
Kuang  et al.
(2008)
RCT Y 60 PC (F) Genital herpes
(damp-heat)
3 longdan xiegan
tang (S)
U R score of symptoms, ER
Yang  and
Liu
(2007)
CCT N 68 PC (F) Sinusitis 2 Self-made
formula (S)
U U ER
Lv  et al.
(2007)
RCT N 60 PC (F) End stage liver
failure
2 Self-made
formula (S)
1/3 R ER, TCM syndrome
scores, blood ammonia,
Endotoxin
Zeng  et al.
(2006)
RCT N 60 U Acute bronchitis
(lung qi obstruction,
retention of ﬂuid)
2 xiaoqinglong
tang (S)
U R ER, improvement of
TCM symptoms
Zhang  et al.
(2006)
RCT N 173 PD Angina pectoris
(deﬁciency of qi and
yin)
4 zhigancao tang
(S)
= R ER, electrocardiogram
Feng  et al.
(2005)
RCT N 80 PC (F) Acute urinary tract
infection
(damp-heat)
2 bazheng san (S) = R ER, average time of
take effect, daily cost
Liu  et al.
(2005)
RCT N 648 U Pregnant women  3 Lithospermum
(S)
= R rate of complete
abortion, average time
of bleeding
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Table 1 (Continued)
Study Design Fund Sample size Granule
source
Disease and TCM
diagnosis
Groups Formula and its
component
Medicine
dosage (G
vs D)
Decoction
prepara-
tion
Outcome measure
Pan et al.
(2005)
RCT N 153 PC (U) Chronic prostatitis 3 Self-made
formula (S)
= R ER, TCM syndrome
scores
Guo  and
Zhao
(2004)
RCT N 82 PD Herpes zoster
(damp-heat)
2 Self-made
formula (S)
= R ER, time of recovery
Sun  (2004) RCT N 195 PC (U) Psoriasis vulgaris 3 Self-made
formula (S)
< R ER
Li  (2003) RCT N 120 U Acute tonsillitis,
upper respiratory
tract infection
(exogenous
wind-heat)
2 Self-made
formula (S)
= R ER
Peng  et al.
(2003)
RCT N 30 PD Viral hepatitis A
(damp-heat)
2 Self-made
formula (S)
U R Recovery dates of
disease, recovery dates
of  ALT and TBIL (d)
Lv  et al.
(2003)
RCT Y 120 PC (U) Primary
osteoporosis
2 Self-made
formula (S)
= U ER, bone mineral
density, improvement
and remission of low
back pain
Zhai  (2003) RCT N 100 PC (U) Cold (wind-heat) 2 Self-made
formula (S)
= R cure rate
Sun  et al.
(2003)
RCT N 121 PC (U) Primary gout
hyperuricemia
2 Self-made
formula (S)
= R ER, uric acid
Qian  et al.
(2003)
CCT N 138 PC (U) Post-
chemotherapeutic
leucopenia
3 Self-made
formula (S)
= U cases of
post-chemotherapeutic
leukopenia
Zhang  et al.
(2002)
RCT N 60 PC (U) Inﬂuenza 2 Modiﬁed
chaihu guizhi
tang (S)
= R ER, symptoms
improvement time
Yu  et al.
(2002)
RCT N 100 PC (U) Deﬁciency of spleen
qi
2 xiangsha
liujunzi tang (S)
1/2 U ER, TCM syndrome
scores
Lin  et al.
(2001)
CCT Y 187 U Eczema 3 Self-made
formula (S)
< U ER
Hu  and
Wang
(2000)
CCT N 1982 PC (U) Headache,
insomnia, nervous
disorders,
hyperthyroidism
and breast ﬁbrosis
2 Unclear (S) 1/2∼2/3 P ER
Bei  and
Xiong
(2000)
RCT N 132 PC (U) Four syndromes of
TCM
2 pingwei san,
sangju yin,
sanren tang,
xiaoyao san (C)
= U ER
Hu  and
Zeng
(2000)
CCT Y 131 PC (U) shaoyang syndrome
(upper respiratory
tract infection,
acute and chronic
gastritis, gastric
ulcer, hepatitis)
2 xiaochaihu tang
(S)
= R ER
Qi  et al.
(1999)
RCT N 1200 U Coronary heart
disease,
hypertension, type
2 diabetes
2 Self-made
formula (C)
= U ER, TCM syndrome
scores,
electrocardiogram,
blood glucose, urine
glucose, blood lipid and
hematological indexes
Cheng and
Zhu
(1999)
RCT N 60 U Stomach pain (qi
stagnation)
2 chaihu shugan
san (S)
= R ER, improvement from
gastroscope
Li  et al.
(1999)
CCT N 200 PD Cough (exogenous
cold- retention of
ﬂuid)
2 xiaoqinglong
tang (S)
= U ER, dates of cough
remission
Zhou  et al.
(1999)
RCT N 80 PD ankylosing
spondylitis
3 self-made
formula (S)
1/4 R ER, symptoms, signs
and laboratory
examination indexes
Zhang
(1998)
CCT  N 100 PC (F) Non-acute
cholecystitis
2 Self-made
formula (S)
= R ER, time of symptoms
improvement
Xu  et al.
(1998)
RCT N 93 U Peptic ulcer, chronic
gastritis
3 buzhong yiqi
tang (unclear)
U U ER
Du  and Xie
(1998)
RCT N 90 PD Exogenous fever 3 yinqiao san (S) = R ER
Wang et al.
(1998)
CCT N 60 PC (U) Wind-cold-wet
syndrome (cold,
vomiting, diarrhea)
2 huoxiang
zhengqi san (S)
= R ER, improvement of
vomiting, abdominal
pain, diarrhea and
fever, blood, stool
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Table 1 (Continued)
Study Design Fund Sample size Granule
source
Disease and TCM
diagnosis
Groups Formula and its
component
Medicine
dosage (G
vs D)
Decoction
prepara-
tion
Outcome measure
Qiu et al.
(1998)
CCT N 82 U Chronic hepatitis B
(spleen deﬁciency
and dampness-heat
with blood stasis)
3 Self-made
formula
(unclear)
U U ER, negative
conversion rate of
HBsAg and HBV-DNA,
liver function
Gao  et al.
(1998)
CCT N 62 U Acute hepatitis E 2 Self-made
formula (S)
U U ER, improvement of
symptoms and signs,
liver function, serum
viral markers
Zhang  and
Huang
(1996)
RCT N 100 U Damp stagnation 2 huoxiang
zhengqi san (S)
= R ER
Shao
(1996)
RCT  N 62 U Stomach pain of qi
stagnation
2 chaihu shugan
san (S)
= R ER, improvement of
symptoms, laboratory
examination
Liang  and
Li (1995)
RCT Y 60 PD Acute cerebral
hemorrhage of gan
yang hua feng
2 Self-made
formula (C)
= R ER, improvement of
symptoms
Zhu  et al.
(1995)
CCT N 373 PD yin deﬁciency of
kidney
3 Series of liuwei
dihuang wan
formula (C)
= R ER, laboratory
examination
Tian  et al.
(1985)
CCT N 167 PC (F) Stomach pain 2 Self-made
formula (C)
U U ER
Xu  (1980) CCT N 135 U Rheumatoid
arthritis
5 Tripterygium
(S)
< U ER
G: granule; D: decoction; RCT: randomized controlled trial; CCT: control clinical trial; Y: yes; N: no; PC: pharmaceutical company; PD: pharmacy department of setting
h rcher
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Dospital; U: unclear; F: free of charge; S: single; C: compound; R: prepared by resea
Xie and Li, 2010) that reported the superiority of granules over
 decoction when sishen wan was used as an enema for mod-
rate colitis (MD: 0.71; 95% CI: [0.59, 0.83]), the results in all
he trials showed no signiﬁcant difference between the decoc-
ion and granule using groups. These results are presented in
able 2.
.2.3. Adverse effects
23 trials (Xu, 1980; Liang and Li, 1995; Shao, 1996; Zhang and
uang, 1996; Xu et al., 1998; Qi et al., 1999; Zhou et al., 1999; Hu
ig. 1. Selection of clinical trials comparing granules and decoction. CNKI: China National K
atabase; CBM: Chinese Biomedical Literature Database; Wanfang: Wanfang database; Rs; P: prepared by patients; ER: effective rate; TCM: traditional Chinese medicine.
and Zeng, 2000; Hu and Wang, 2000; Lin et al., 2001; Lv et al., 2003,
2007; Qian et al., 2003; Sun et al., 2003; Liu et al., 2005; Lu et al.,
2008; Kuang et al., 2008; Liao et al., 2009; Wang et al., 2009; Wei
et al., 2009a,b; Huang and Zhu, 2009; Xie and Li, 2010) reported
mild adverse effects; no severe adverse effects were reported in
the studies. No statistical differences were found in the rate of mild
adverse effects occurring between decoction and granule groups.
The review demonstrated that Chinese herbal medicine granules
were safe.
nowledge Infrastructure Databases; VIP: Chinese Science and Technology Periodical
CTs: randomized controlled trials; CCTs: controlled clinical trials.
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Table 2
Effect estimates of the included studies.
Study Intervention (G vs D) Effect index RR/MD 95%CI
Tan and Tan (2010) Self-made granules (n = 50) vs
self-made decoction (n = 50)
Effective rate 0.98 [0.86, 1.11]
Yang  et al. (2010) Self-made granules (n = 19) vs
self-made decoction (n = 18)
Effective rate 1.07 [0.83, 1.39]
Qin  (2010) tianma gouteng yin granules
(n = 22) vs tianma gouteng yin
decoction (n = 18)
Effective rate 0.98 [0.79, 1.21]
Xie  and Li (2010) sishen wan granules (n = 58) vs
sishen wan decoction (n = 43)
Sutherland index 0.71 (MD) [0.59, 0.83]
Liao  et al. (2009) buyang huanwu tang granules
(n = 30) vs buyang huanwu tang
decoction (n = 30)
Effective rate 1.14 [0.87, 1.49]
Wei  et al. (2009a) liangfu wan granules (n = 52) vs
liangfu wan decoction (n = 51)
Effective rate 1.02 [0.91, 1.15]
Huang  and Zhu (2009) qingjin tangjiang granules + placebo
of  decoction (n = 58) vs qingjin
tangjiang decoction + placebo of
granules (n = 58)
Effective rate 1.00 [0.89, 1.12]
Zhou  et al. (2009) Self-made granules enema (n = 20)
vs self-made decoction enema
(n = 20)
Effective rate 1.11 [0.93, 1.31]
Chen  et al. (2009) Self-made granules (n = 55) vs
self-made decoction (n = 50)
Effective rate 1.01 [0.90, 1.13]
Wei  et al. (2009a) Self-made granules (n = 50) vs
self-made decoction (n = 38)
SCr (umol/L); BUN
(mmol/L)
SCr: −13.64(MD);
BUN: 0.34(MD)
SCr: [−41.80,
14.52]; BUN:
[−1.49, 2.17]
Zhao  et al. (2009) Self-made granules (n = 43) vs
self-made decoction (n = 43)
Effective rate 0.98 [0.89, 1.07]
Xiang  et al. (2009) Self-made granules (n = 105) vs
self-made decoction (n = 127)
ALT (U/L), AST
(U/L), TBil (mol/L)
ALT: 1.07 (MD);
AST: −1.67(MD);
TBil: −0.81(MD)
ALT: [−4.82, 6.96];
AST: [−8.36, 5.02]
TBil: [−8.04, 6.42]
Zhang and Cai (2009) Self-made granules (n = 35) vs
self-made decoction (n = 30)
Effective rate 1.04 [0.93, 1.16]
Wang  et al. (2009) Self-made granules + placebo of
decoction (n = 26) vs self-made
decoction + placebo of granules
(n = 27)
Effective rate 1.08 [0.95, 1.22]
Zhou  et al. (2008) Self-made granules (n = 36) vs
self-made decoction (n = 36)
Pittsburgh Sleep
Quality Index
(PSQI)
−0.24(MD) [−1.85, 1.37]
Lu  et al. (2008) huoxiang zhengqi san
granules + placebo of decoction
(n = 36) vs huoxiang zhengqi san
decoction + placebo of granules
(n = 36)
Effective rate 1.00 [0.89, 1.13]
Yang  et al. (2008) Self-made granules (n = 40) vs
self-made decoction (n = 100)
Volume of uterine
ﬁbroids (cm3)
−0.66 (MD) [−6.13, 4.81]
Li  et al. (2008) Self-made granules (n = 25) vs
self-made decoction (n = 25)
Effective rate 1.16 [0.89, 1.51]
Kuang  et al. (2008) longdan xiegan tang granules
(n = 20) vs longdan xiegan tang
decoction (n = 20)
Effective rate 1.00 [0.81, 1.23]
Yang  and Liu (2007) Self-made granules (n = 38) vs
self-made decoction (n = 30)
Cure rate 1.04 [0.67, 1.61]
Lv  et al. (2007) Self-made granules (n = 20) vs
self-made decoction (n = 22)
Blood ammonia,
Endotoxin
NH3: 3.19 (MD);
ETM: −0.00 (MD).
NH3: [−9.92,
16.30]; ETM:
[−0.02, 0.02]
Zeng  et al. (2006) xiaoqinglong tang granules (n = 30)
vs xiaoqinglong tang decoction
(n = 30)
Cure rate 1.11 [0.53, 2.34]
Zhang  et al. (2006) zhigancao tang granules (n = 43) vs
zhigancao tang decoction (n = 43)
ECG improvement
rate
1.19 [0.88, 1.62]
Feng  et al. (2005) bazheng san granules (n = 42) vs
bazheng san decoction (n = 38)
Effective rate 1.03 [0.92, 1.16]
Liu  et al. (2005) Lithospermum granules (n = 217)
vs lithospermum decoction
(n = 221)
Complete abortion
rate
1.00 [0.97, 1.03]
Pan  et al. (2005) Self-made granules enema (n = 50)
vs self-made decoction enema
(n = 53)
Effective rate 1.03 [0.91, 1.16]
Guo  and Zhao (2004) Self-made granules (n = 42) vs
self-made decoction (n = 40)
Cure rate 1.06 [0.78, 1.44]
Sun  (2004) Self-made granules (n = 104) vs
self-made decoction (n = 35)
Effective rate 0.98 [0.89, 1.08]
Li  (2003) Self-made granules (n = 60) vs
self-made decoction (n = 60)
Effective rate 1.00 [0.91, 1.10]
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Table 2 (Continued)
Study Intervention (G vs D) Effect index RR/MD 95%CI
Peng et al. (2003) Self-made granules (n = 30) vs
self-made decoction (n = 30)
Recovery dates of
ALT and TBIL (d)
ALT: 1.01 (MD);
TBIL: −0.48 (MD)
ALT: [−36.74, 38.76];
TBIL: [−37.52, 36.56]
Lv  et al. (2003) Self-made granules (n = 64) vs
self-made decoction (n = 56)
Bone mineral
density (g/cm2)
0.01 (MD) [−0.04, 0.06]
Zhai  (2003) Self-made granules (n = 50) vs
self-made decoction (n = 50)
Cure rate 1.02 [0.92, 1.14]
Sun  et al. (2003) Self-made granules (n = 40) vs
self-made decoction (n = 41)
Uric acid (mol/L) 3.85 (MD) [−33.46, 41.16]
Qian  et al. (2003) Self-made granules (n = 50) vs
self-made decoction (n = 46)
Rate of post-
chemotherapeutic
leukopenia
0.95 [0.69, 1.31]
Zhang  et al. (2002) Modiﬁed chaihu guizhi tang granules
(n = 30) vs modiﬁed chaihu guizhi
tang decoction (n = 30)
Defervescence time
(h)
1.64 (MD) [−1.80, 5.08]
Yu  et al. (2002) xiangsha liujunzi tang granules
(n = 50) vs xiangsha liujunzi tang
decoction (n = 50)
Effective rate 1.04 [0.93, 1.17]
Lin  et al. (2001) Self-made granules (n = 63) vs
self-made decoction (n = 65)
Cure rate 0.88 [0.63, 1.25]
Hu  and Wang (2000) Self-made granules (n = 803) vs
self-made decoction (n = 1179)
Effective rate Headache: 0.99
insomnia: 0.98
nervous disorders:
0.99
hyperthyroidism:
1.02 breast
ﬁbroids: 1.00
Headache: [0.96, 1.03]
insomnia: [0.94, 1.02]
nervous disorders:
[0.95, 1.02]
hyperthyroidism:
[0.97, 1.09] breast
ﬁbroids: [0.95, 1.07]
Bei  and Xiong (2000) Self-made granules (n = 66) vs
self-made decoction (n = 66)
Effective rate 0.98 [0.88, 1.10]
Hu  and Zeng (2000) xiaochaihu tang granules (n = 68) vs
xiaochaihu tang decoction (n = 63)
Effective rate 0.99 [0.91, 1.07]
Qi  et al. (1999) Self-made granules (n = 800) vs
self-made decoction (n = 400)
Effective rate Coronary heart
disease: 1.03
hypertension: 1.02
type 2 diabetes:
1.02
Coronary heart
disease: [0.97, 1.10]
hypertension: [0.96,
1.08] type 2 diabetes:
[0.97, 1.08]
Cheng  and Zhu (1999) chaihu shugan san granules (n = 68) vs
chaihu shugan san decoction (n = 63)
Effective rate 1.24 [0.94, 1.63]
Li  et al. (1999) xiaoqinglong tang granules (n = 100)
vs xiaoqinglong tang decoction
(n = 100)
Cough remission
time (d)
−0.10 (MD) [−0.33, 0.13]
Zhou  et al. (1999) Self-made granules (n = 42) vs
self-made decoction (n = 18)
Effective rate 1.01 [0.88, 1.15]
Zhang  (1998) Self-made granules (n = 50) vs
self-made decoction (n = 50)
Effective rate 1.05 [0.89, 1.23]
Xu  et al. (1998) buzhong yiqi tang granules (n = 33) vs
buzhong yiqi tang decoction (n = 32)
Effective rate 1.01 [0.82, 1.24]
Du  and Xie (1998) yinqiao san granules (n = 30) vs
yinqiao san decoction (n = 30)
Effective rate 1.00 [0.91, 1.10]
Wang  et al. (1998) huoxiang zhengqi san granules
(n = 30) vs huoxiang zhengqi san
decoction (n = 30)
Effective rate 1.00 [0.94, 1.07]
Qiu  et al. (1998) self-made granules (n = 33) vs
self-made decoction (n = 34)
Negative
conversion rate of
HBsAg and
HBV-DNA
HBsAg: 0.92
HBV-DNA: 1.04
HBsAg: [0.53, 1.60]
HBV-DNA: [0.59, 1.83]
Gao  et al. (1998) Self-made granules (n = 31) vs
self-made decoction (n = 31)
Cure rate 2.00 [0.19, 20.93]
Zhang  and Huang (1996) huoxiang zhengqi san granules
(n = 50) vs huoxiang zhengqi san
decoction (n = 50)
Effective rate 1.02 [0.93, 1.12]
Shao  (1996) chaihu shugan san granules (n = 31) vs
chaihu shugan san decoction (n = 31)
Effective rate 1.07 [0.94, 1.22]
Liang  and Li (1995) Self-made granules (n = 30) vs
self-made decoction (n = 30)
Hematoma
absorption rate
0.99 [0.78, 1.25]
Zhu  et al. (1995) liuwei dihuang wan granules (n = 41)
vs liuwei dihuang wan decoction
(n = 41)
Effective rate 1.00 [0.95, 1.05]
Tian  et al. (1985) Self-made granules (n = 101) vs
self-made decoction (n = 66)
Effective rate 1.01 [0.97, 1.04]
Xu  (1980) Tripterygium granules (n = 5) vs
tripterygium decoction (n = 75)
Effective rate 0.67 [0.33, 1.38]
G: granule; D: decoction; RR: risk ratio; MD:  mean difference; CI: conﬁdence interval.
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.3. Characteristic of interventions
.3.1. Arms of interventions
The numbers of treatment arms in the trials can be seen
n Table 1. 62.5% (35/56) of the trials had two arms (granules
nd decoction); 33.9% (19/56) had three arms; 3.5% (2/56) had
our or ﬁve arms. Besides granules and decoction, the interven-
ions included placebo, western medicine, other Chinese herbal
edicines, and waiting list controls. In some trials, all the partici-
ants used conventional western medicines.
.3.2. Formulae used in interventions
20 trials researched traditional CHM formulas, including tianma
outeng yin (Qin, 2010), sishen wan (Xie and Li, 2010), buyang
uanwu tang (Liao et al., 2009), liangfu wan (Wei  et al., 2009b),
uoxiang zhengqi san (Zhang and Huang, 1996; Wang et al., 1998; Lu
t al., 2008), longdan xiegan tang (Kuang et al., 2008), xiaoqinglong
ang (Li et al., 1999; Zeng et al., 2006), zhigancao tang (Zhang et al.,
006), bazheng san (Feng et al., 2005), chaihu guizhi tang (Zhang
t al., 2002), xiangsha liujunzi tang (Yu et al., 2002), xiaochaihu tang
Hu and Zeng, 2000), chaihu Shugan san (Shao, 1996; Cheng and
hu, 1999), buzhong yiqi tang (Xu et al., 1998), yinqiao san (Du and
ie, 1998), and liuwei dihuang wan (Zhu et al., 1995). Another 38
rials researched self-made formulas, of which 2 trials were sin-
le herbs: lithospermum (zicao) (Liu et al., 2005) and tripterygium
leigongteng) (Xu, 1980).
.3.3. Sources of granules
According to the studies, granules were mainly sourced from
harmaceutical companies and pharmacy departments in hos-
itals. Sources of granules in 33 trials were pharmaceutical
anufacturers in China, all of whom were authorized to produce
ranules. 13 trials stated that granules were provided by pharma-
eutical companies free of charge, while 20 trials reported their
ranules were from pharmaceutical companies, but the authors did
ot specify whether their granules were free of charge. To evaluate
hether granules provided and funded by pharmaceutical compa-
ies could be an important source of bias in this review, we analyzed
he results of the 13 relevant trials, and found that there were no
igniﬁcant differences in mean outcome related to the provider or
under of the products being evaluated. The data from this sub-
roup was consistent with the overall results of the 56 included
rials. 9 trials reported that their granules were made by the phar-
acy departments in their own hospitals. 14 trials did not report
he source of granules. Details on sources of granules are presented
n Table 1.
.3.4. Dosage and preparation of granules and decoction
In 32 trials (Liang and Li, 1995; Zhu et al., 1995; Shao, 1996;
hang and Huang, 1996; Zhang, 1998; Du and Xie, 1998; Wang
t al., 1998; Cheng and Zhu, 1999; Qi et al., 1999; Li et al., 1999,
008; Bei and Xiong, 2000; Hu and Zeng, 2000; Zhang et al., 2002,
006; Li, 2003; Lv et al., 2003; Qian et al., 2003; Sun et al., 2003; Zhai,
003; Guo and Zhao, 2004; Liu et al., 2005; Feng et al., 2005; Pan
t al., 2005; Lu et al., 2008; Zhou et al., 2008, 2009; Chen et al., 2009;
iang et al., 2009; Zhao et al., 2009; Xie and Li, 2010; Yang et al.,
010), the dosage of granules was equivalent to the decoction; in
 trials (Xu, 1980; Zhou et al., 1999; Hu and Wang, 2000; Lin et al.,
001; Yu et al., 2002; Sun, 2004; Lv et al., 2007; Liao et al., 2009;
ei  et al., 2009a),  the dosage of granules was 1/4–2/3 of that of the
ecoction; another 15 trials (Tian et al., 1985; Gao et al., 1998; Qiu
t al., 1998; Xu et al., 1998; Peng et al., 2003; Zeng et al., 2006; Yang
nd Liu, 2007; Kuang et al., 2008; Yang et al., 2008; Zhang and Cai,
009; Huang and Zhu, 2009; Wang et al., 2009; Wei  et al., 2009b;
in, 2010; Tan and Tan, 2010)did not reported whether the dosageacology 140 (2012) 555– 567 563
of granules were equivalent to the decoction. Details on dosage are
presented in Table 1.
2 trials (Qiu et al., 1998; Xu et al., 1998) did not report on the
preparation of granules; granules in 9 trials (Tian et al., 1985; Liang
and Li, 1995; Zhu et al., 1995; Qi et al., 1999; Bei and Xiong, 2000;
Huang and Zhu, 2009; Liao et al., 2009; Zhou et al., 2009; Qin, 2010)
were patent medicine granules, which involved the preparation of a
traditional decoction of a formula of individual herbs that was then
concentrated, dried and extracted to produce herbal granules (Ltd
Jiangyin Tianjiang Pharmaceutical Co., 2011); In another 45 trials,
the preparation of granules comprised aggregated mixtures of dif-
ferent single herbal granules for individualized prescription. All the
individual granules had been prepared in advance by pharmaceuti-
cal companies or pharmacy departments of hospitals. In the trials,
individual herb granules were formulated to match the decoction,
and then mixed with boiling water for a few minutes, without the
protracted boiling process that characterizes decoctions. Details on
this issue are presented in Table 1.
Standardization of interventions is usually required in clini-
cal trials. The method of CHM preparation in the decoction group
(control group) should also be identical for each participant in a
TCM clinical trial in order to reduce the performance bias and to
compare and evaluate the effect between the decoction and other
control treatments. In this review, 35 included trials used stan-
dardized methods of preparation reported by researchers, 1 trial
reported that the decoction was prepared by the patients them-
selves, 20 trials did not report any information about preparation
of the decoction (Table 1).
3.4. Sources of funding
12 trials (Liang and Li, 1995; Hu and Zeng, 2000; Lin et al., 2001;
Lv et al., 2003; Kuang et al., 2008; Lu et al., 2008; Huang and Zhu,
2009; Liao et al., 2009; Wang et al., 2009; Wei  et al., 2009b; Xiang
et al., 2009; Yang et al., 2010) reported that they were supported by
research funding from central and local government. The other 44
trials did not mention sources of funding. None of the trials reported
funding from other organizations or pharmaceutical companies.
3.5. Health economic evaluation
3 trials (Hu and Wang, 2000; Feng et al., 2005; Tan and Tan,
2010) reported health economic outcomes; all the trials showed
that the price of granules in China is currently higher than that of
decoctions by between 16.61% and 312%.
4. Discussion
4.1. Analysis of effectiveness and safety
The results of this review suggest that there is no signiﬁ-
cant difference in effectiveness and safety between Chinese herbal
medicine granules and decoctions.
Meta-analysis could not be employed due to the inconsistency
and heterogeneity of study design, participants, diseases, inter-
ventions, controls, and outcome measures; nearly all the trials
(98.2%) reported no difference in outcomes between granules and
decoctions, and the remaining single trial’s results showed the
superiority of granules over decoction. We  evaluated the safety
reports from the granules: no serious adverse effects were reported
in the studies. No statistical differences were found in the rate of
mild adverse effects occurring between the decoction and granule
groups.
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.2. Limitation of the systematic review
.2.1. Methodological quality and design of included studies
The methodological quality of the included RCTs was  poor. The
esigns of the majority of trials were also problematic. Only 3 trials
entioned that their research used a non-inferiority study designs
o compare the effectiveness of decoction and granules. It seemed
hat most researchers lacked knowledge of the appropriate clinical
esearch methodology. This was particularly apparent when com-
aring the effectiveness of a new herbal drug versus a controlled
erbal drug of known and proven effectiveness. In this situation
ost researchers publishing in this ﬁeld were still using a con-
entional clinical trial design and inappropriate statistical methods
or signiﬁcance testing. They did not apply methods used for non-
nferiority, equivalence and superiority within their trial designs.
his means the results of this systematic review should be inter-
reted with caution.
.2.2. Potentially publication bias
None of the trials reported negative or non equivalence out-
ome. A greater than 98% rate of equivalence seems a little too good
o be true and may  be a reﬂection of publication bias in this sys-
ematic review. Although we searched the trials as systematically
nd comprehensively as possible, it seemed such publication bias
as inevitable. This phenomenon maybe related to a reluctance to
ublish negative or conﬂicting data.
.2.3. Declaring potential conﬂicts of interest
78.6% (44/56) of trials did not report exactly how their trials had
een funded; 30.4% (17/56) of trials did not report the source of
ranules. 58.9% (33/56) of trials mentioned that they used granules
rom pharmaceutical companies, of which 60.6% (20/33) failed to
eport whether the granules were provided free by pharmaceuti-
al companies. The publication of a trial has a direct relationship
ith trial funding and trials supported by companies are more
ikely to report positive results than those supported by govern-
ent or other academic organizations (Liu, 2009). Consequently
here maybe some risk of bias for some included trials in this review
hich did not report these potential conﬂicts of interest.
.2.4. Inconsistency of dosages between granules and decoction
The dosages between granules and decoction were the same
n 57.1% (32/56) of trials; the dosages of granules was  lower than
hose of decoction in 16.1% (9/56) of trials; 26.8% (15/56) of trials
id not reported information on this issue. It seemed that there was
ome inconsistency of dosages in clinical research when comparing
ranules and decoctions concurrently that raises additional ques-
ions about the rigor and validity of these ﬁndings. However trials
hat used a lower dose for granules than decoction also reported
quivalent clinical outcomes for the two approaches. In addition,
n 9 trials, granules were manufactured by the hospitals themselves
ithout any details on preparation, which were questionable. Such
eterogeneities should be avoided in future trials.
.2.5. Inconsistency of prescription methods among granules
As reported in Section 3.3.4, there was an inconsistency with
espect to how the granules were formulated in the included trials
2 trials did not report on the preparation of granules, granules in
 trials were derived from decoctions of standardized herbal for-
ulae, 45 trials used granules comprising aggregated mixtures of
ifferent single herbal granules). In the trials that used mixtures
f different single herbal granules prescriptions were individual-
zed for each patient. Since there is currently no formal deﬁnition of
granules for prescription’ from the Chinese government’s pharma-
opoeia (SATCM of China Editorial Committee of Chinese Materiaacology 140 (2012) 555– 567
Medica, 1999), we would encourage the next edition of the phar-
macopoeia (in 2015) to add a general chapter on granules for
prescription, so as to avoid this inconsistency.
4.3. Clinical implications for Chinese practitioners using Chinese
herbal medicine granules
The data from this review suggests that the aggregated mixtures
of different single herb granules were just as effective as the gran-
ules derived from decoctions of complex herbal formulae in their
respective trials. This has signiﬁcant clinical and research impli-
cations because the CM clinician could, without any diminution
of therapeutic effect, individualize therapy by combining single
herbal granules rather than using the ﬁxed, generic formulae avail-
able via granules from complex decoctions. However, the poor
methodological quality of these trials means that we  should be very
circumspect about how we  interpret these data. Once again more
rigorous research is required to conﬁrm or refute these preliminary
ﬁndings.
5. Conclusion and recommendations
There are a number of limitations within the data that forms the
basis of this review. The main problems with the included stud-
ies were related to their scientiﬁc quality, design and reporting
all of which may  create bias. Our initial and tentative conclu-
sions will certainly require further research involving better study
design, methodology and transparency, in particular the use of non-
inferiority or equivalence designs (Huang and Zhao, 2007). We  also
suggest that researchers must pay attention to the dose of granules
and decoctions, improve the quality of trials, and report the study
and its funding in the normal manner within a CONSORT statement
(Moher et al., 2010).
The results of this review provide preliminary data suggesting
that CHM granules may  have the same effectiveness and safety as
decoctions. However, the poor methodological quality of most of
the included trials means that we are unable to reach a deﬁnitive
conclusion that both Chinese herbal medicine granules and decoc-
tions have the same degree of effectiveness and safety in clinical
practice. We  suggest that, subject to more and better research,
studies should focus on using quality controlled granules manufac-
tured by well regulated pharmaceutical companies to treat clearly
deﬁned syndromes or diseases. Comparisons of standardized vs
individualized treatments, and aggregated granules vs granules
derived from complex decoctions are important secondary ques-
tions for CHM that need to be addressed as a matter of some
urgency.
Granular preparations can be recommended for clinical use as
they are safe and certainly simpler to control, produce and man-
age as a consistent medical product than decoctions. If granules
are to be used more widely in China, then pharmaceutical compa-
nies and hospitals must reduce their production and distribution
costs to lower the price of granules and make them a more realis-
tic and competitive option for clinicians and patients. Furthermore
the government should consider including the use of granule based
herbal preparations as part of Chinese medical health insurance
if they wish them to be more widely used. In the West, granules
are considerably cheaper to dispense than the dried herbs used for
decoctions so these obstacles to the wider use of granules do not
arise.
We  believe this review provides a rational argument for the
continued investigation and use of granules. They can provide a
more consistent herbal product that will improve our ability to reg-
ulate and research Chinese Herbal Medicines internationally. We
believe that further more rigorous and accurate pharmacological,
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